Kymera Therapeutics, Inc.

NasdaqGM:KYMR Voorraadrapport

Marktkapitalisatie: US$2.9b

Kymera Therapeutics Toekomstige groei

Future criteriumcontroles 1/6

De winst van Kymera Therapeutics zal naar verwachting dalen met 10% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 16.2% per jaar. De winst per aandeel zal naar verwachting dalen met 5.4% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -98.5% zijn.

Belangrijke informatie

-10.0%

Groei van de winst

-5.4%

Groei van de winst per aandeel

Biotechs winstgroei28.4%
Inkomstengroei16.2%
Toekomstig rendement op eigen vermogen-98.5%
Dekking van analisten

Good

Laatst bijgewerkt18 Nov 2024

Recente toekomstige groei-updates

Recent updates

Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Nov 04
Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors

Oct 06

Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results

Aug 11
Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 27% Share Price Surge Not Quite Adding Up

Jul 14
Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 27% Share Price Surge Not Quite Adding Up

Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being

Jun 12
Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being

We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth

May 03
We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth

Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith

Mar 21

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43

Feb 25
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43

Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking

Feb 17
Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up

Dec 29
Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up

We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully

Nov 06
We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully

Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts

Aug 31
Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts

Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

Aug 04
Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up

May 21
Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up

We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely

Apr 16
We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely

Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth

Dec 28
Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth

Winst- en omzetgroeiprognoses

NasdaqGM:KYMR - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/202653-300-216-25616
12/31/202564-265-225-18019
12/31/202455-210-221-17018
9/30/202488-167-148-125N/A
6/30/202489-158-138-106N/A
3/31/202479-155-136-98N/A
12/31/202379-147-137-103N/A
9/30/202347-167-174-150N/A
6/30/202352-158-169-153N/A
3/31/202347-159-163-157N/A
12/31/202247-155-156-153N/A
9/30/202246-154-155-152N/A
6/30/202257-139-157-155N/A
3/31/202264-124-148-146N/A
12/31/202173-100-131-129N/A
9/30/202170-79-113-111N/A
6/30/202165-585458N/A
3/31/202149-486977N/A
12/31/202034-557988N/A
9/30/202023-539097N/A
6/30/20209-57-52-47N/A
3/31/20206-52-17-15N/A
12/31/20193-411718N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat KYMR de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat KYMR de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat KYMR de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van KYMR ( 16.2% per jaar) zal naar verwachting sneller groeien dan de markt US ( 9% per jaar).

Hoge groei-inkomsten: De omzet van KYMR ( 16.2% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat KYMR binnen 3 jaar verliesgevend zal zijn.


Ontdek groeibedrijven